BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

· Issued by BioCryst Pharmaceuticals, Inc.

On 6ix: 6ix.com/news/biocryst-presents-new-data-acaai-highlighting-burden-hae-pediatric-patients-and

Watch BioCryst Pharmaceuticals' latest callBioCryst Pharmaceuticals (NASDAQ:BCRX) Q3 2026 Earnings Call · Replay · Nov 4Read the transcript of BioCryst Pharmaceuticals (NASDAQ:BCRX) Q3 2026 Earnings Call

–  Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers –

–  ORLADEYO oral granules demonstrated early and sustained reduction in HAE attacks over one year of treatment in second interim analysis of APeX-P –

–  ORLADEYO oral granules are currently under review with U.S. FDA for ages 2 to

BioCryst Pharmaceuticals, Inc. on 6ix

Story so far

Earlier from BioCryst Pharmaceuticals

Later from BioCryst Pharmaceuticals

All BioCryst Pharmaceuticals news releases